Prophylaxis of DVT following hip or knee replacement ...
See full prescribing information for complete boxed warning. (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if …
Download Prophylaxis of DVT following hip or knee replacement ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION • …
packageinserts.bms.comFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Unresectable or Metastatic Melanoma • OPDIVO® (nivolumab) as a single agent is indicated for the treatment of patients
PATIENT INFORMATION SPRYCEL (Spry-sell) …
packageinserts.bms.com(imatinib mesylate). • adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who no longer benefit from, or did not tolerate, other treatment.
MEDICATION GUIDE ELIQUIS (ELL eh kwiss) …
packageinserts.bms.com39 . MEDICATION GUIDE . ELIQUIS (ELL eh kwiss) (apixaban) tablets . What is the most important information I should know about ELIQUIS? • …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
packageinserts.bms.comFULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Adult Rheumatoid Arthritis (RA) ORENCIA® (abatacept) is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
HIGHLIGHTS OF PRESCRIBING INFORMATION - BMS
packageinserts.bms.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY.
KENALOG -40 INJECTION - BMS
packageinserts.bms.comKENALOG -40 INJECTION (triamcinolone acetonide injectable suspension, USP) NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . For Intramuscular or Intra-articular Use Only
PATIENT INFORMATION ORENCIA (abatacept) for injection, …
packageinserts.bms.comPATIENT INFORMATION ORENCIA® (oh-REN-see-ah) (abatacept) for injection, for intravenous use ORENCIA® (oh-REN-see-ah) (abatacept) injection, for subcutaneous use What is …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
packageinserts.bms.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRAVACHOL safely and effectively. See full prescribing information for
HIGHLIGHTS OF PRESCRIBING INFORMATION Cardiac …
packageinserts.bms.comFULL PRESCRIBING INFORMATION SPRYCEL® (dasatinib) 1 INDICATIONS AND USAGE SPRYCEL® (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid
HIGHLIGHTS OF PRESCRIBING INFORMATION BARACLUDE …
packageinserts.bms.comDecompensated Liver Disease The recommended dose of BARACLUDE for chronic hepatitis B virus infection in adults with decompensated liver disease is 1 mg once daily. 2.3 Recommended Dosage in Pediatric Patients Table 1 describes the recommended dose of BARACLUDE for pediatric patients 2 years of age or older and weighing at least 10 kg.
Related documents
Prescribing Information | SUBLOCADE® (buprenorphine ...
www.sublocade.comSee full prescribing information for SUBLOCADE. SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use, CIII Initial U.S. Approval: 2002 WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY See full prescribing information for complete …
HIGHLIGHTS OF PRESCRIBING INFORMATION BOTOX
media.allergan.comSee full prescribing information for complete boxed warning. The effects of BOTOXand all botulinum toxin products may spread from ... BOTOX is indicated for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.
HIGHLIGHTS OF PRESCRIBING INFORMATION DOSAGE …
seagendocs.comaccordingly (5.1).See full prescribing information for complete boxed warning. † Anaphylaxis and infusion reactions: If an infusion reaction occurs, interrupt the infusion. If anaphylaxis occurs, immediately discontinue the infusion (5.2). † Hematologic toxicities: Monitor complete blood counts. Monitor for signs of infection.
DOSAGE AND ADMINISTRATION HIGHLIGHTS OF …
solirispro.comSee full prescribing information for complete boxed warning Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris and may become rapidly life-threatening or fatal if not recognized and treated early (5.1). outweigh the
DOSAGE FORMS AND STRENGTHS See full prescribing ...
www.austedo.comSee full prescribing information for complete boxed warning. ... VMAT2 inhibitors, including AUSTEDO, may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO in their patients by assessing
HIGHLIGHTS OF PRESCRIBING INFORMATION CAR-positive …
www.novartis.usSee full prescribing information for complete boxed warning. • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with
HIGHLIGHTS OF PRESCRIBING INFORMATION • Inject ...
www.novo-pi.comSee full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid
Prescribing Information | OPZELURA™ (ruxolitinib)
www.opzelura.comSee full prescribing information for complete boxed warning. • • Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving Janus kinase inhibitors for inflammatory conditions. (5.1)